HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

FTC orders Aurobindo to divest 4 drugs to complete $250M Lannett acquisition

Before Aurobindo can complete its acquisition of Pennsylvania generics specialist Lannet, it will have to divest four drugs from the proposed $250 million buyout to resolve anticompetitive concerns, the Federal Trade Commission said.

By FiercePharma · Jun 19, 2026 · via FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Moderna's flu candidate sails through FDA advisory committee in unanimous votes
The WeekFierceBiotech ↗
Moderna's flu candidate sails through FDA advisory committee in unanimous votes
As Moderna reshapes itself in the wake of the pandemic, the company on Thursday passed a key milestone in its …
Jun 19, 2026
Verastem pivots after modest pancreatic cancer data
The WeekBriefing
Verastem pivots after modest pancreatic cancer data
The company will steer R&D toward other pipeline priorities after updated results for its approved combo fell …
Jun 19, 2026
Federal grant delays could jeopardize essential disability services, research
The WeekSTAT News ↗
Federal grant delays could jeopardize essential disability services, research
Disability researchers across the country worry about their jobs, and the future of their institutions, as a d…
Jun 19, 2026